



Attorney Docket No. VPI/03-170 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/821,793
Confirmation No.: 9337
Filing Date: April 9, 2004
Examiner: Not Yet Assigned
Group art unit: 1614
Applicants: Farmer et al.
For: INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE

February 28, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

(a) Pursuant to Rule 56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application. Copies of references A1-A4, B1-B11, and C1-C6 are attached.

- (b) ☒ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
 - ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
 - ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
 - ☒ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three

Applicants: Farmer et al.
Application No.: 10/821,793

months prior to the filing of this Information Disclosure Statement;
or

☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement;
or

☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

(d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and

☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement;
or

☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement;
and

☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,



Michael C. Badia, Reg. No. 51,424

Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6467
Fax: (617) 444-6483

Applicants: Farmer et al.
Application No.: 10/821,793

I hereby certify that this correspondence is being deposited
with the U.S. Postal Service as First Class Mail in an envelope
addressed to Commissioner for Patents, Mail Stop: Amendment,
P.O. Box 1450, Alexandria, VA 22313-1450 on February 28, 2005.



Date of Signature



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/821,793
	Filing Date	April 9, 2004
	First Named Inventor	Luc J. Farmer
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/03-170 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	2002/0123468	Sept. 5, 2002	Han			
	A2	4,499,082	Feb. 12, 1985	Shenvi et al.			
	A3	534,410	Jan. 24, 1995	Du Pont Merck Pharmaceutical Co.			
	A4	5,866,684	Feb. 2, 1999	Attwood et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	98/17679	Vertex Pharmaceuticals, Inc.	30 April 1998		
	B2	WO	01/40262	Du Pont Pharmaceutical Co.	7 June 2001		
	B3	WO	01/74768	Vertex Pharmaceuticals, Inc.	11 October 2001		
	B4	WO	02/08244	Schering Corp.	31 January 2002		
	B5	WO	02/08256	Schering Corp.	31 January 2002		
	B6	WO	02/18369	Eli Lilly and Co.	7 March 2002		
	B7	WO	01/02424	Du Pont Pharmaceuticals Co.	11 January 2001		
	B8	WO	92/12140	Georgia Tech Research Corp.	23 July 1992		
	B9	WO	02/08251	Corvas International Inc.	31 January 2002		
	B10	WO	03/087092	Vertex Pharmaceuticals, Inc.	23 October 2003		
	B11	EP	0 417 721	Merrell Dow Pharmaceuticals Inc.	11 September 1990		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Han et al., α -Ketoamides, α -Ketoesters and α -Diketones as HCV NS3 Protease Inhibitors", Bioorganic & Medicinal Chemistry Letters, Vol. 10, Pages 711-713, 2000.
	C2	Burkhart et al., "Preparation of α -Keto Ester Enol Acetates as Potential Prodrugs of Human Neutrophil Elastase Inhibitors", Bioorganic & Medicinal Chemistry Letters, Vol. 8, No. 1-6, Pages 63-64, 1998.
	C3	Fumihiko Akahoshi, "Chymas Inhibitors and Their Therapeutic Potential", Drugs of the Future, Vol. 27, No. 8, Pages 765-770, 2002.
	C4	Bastos et al., "Inhibitors of Human Heart Chymase Based on a Peptide Library", Proc. Natl. Acad. Sci. USA, Vol. 92, No. 15, Pages 6738-6742, 1995.
	C5	Llinas-Brunet et al., "Studies on the C-Terminal of Hexapeptide Inhibitors of the Hepatitis C Virus Serine Protease", Bioorganic & Medicinal Chemistry Letters, Vol. 8, No. 19, 1998.

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C6	Perni et al., Inhibitors of Hepatitis C Virus NS3.4A Protease 2. Warhead SAR and Optimization", Bioorganic & Medicinal Chemistry Letters, Vol. 14, No. 6, 2004.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Our Docket No.: VPI/03-170 US




Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On February 28, 2005.
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. PTO-1449 Form (2 pages, in duplicate);
3. Cited References (B1-11, C1-6); and
4. This Return Postcard Receipt.



Signature

Kimberly A. Coyne
Typed or printed name of person signing Certificate